DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Faslodex (Fulvestrant) - Current Clinical Trials

 
 



Faslodex Related Clinical Trials

Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer [Active, not recruiting]

Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer [Withdrawn]

Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI [Recruiting]

A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. [Active, not recruiting]

Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer [Completed]

Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer [Terminated]

Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer [Terminated]

Study of AFP464 +/- Faslodex in ER + Breast Cancer [Terminated]

MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer [Active, not recruiting]

Efficacy and Safety of 500mg of Fulvestrant as a First Line Hormonal Treatment in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer [Active, not recruiting]

Second Line Breast Cancer Trial [Completed]

Faslodex 500mg Multiple Dose Tolerability Study in BC Patients [Completed]

AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer [Recruiting]

Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer [Completed]

Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer [Recruiting]

The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer [Recruiting]

Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer [Terminated]

Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery [Suspended]

Faslodex Advanced Breast Cancer Local Chinese Study [Completed]

Fulvestrant With or Without Bortezomib in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer [Active, not recruiting]

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer [Recruiting]

Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure [Completed]

Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer. [Recruiting]

ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial [Terminated]

BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer [Active, not recruiting]

Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer [Active, not recruiting]

A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg [Completed]

Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor [Completed]

Faslodex in McCune Albright Syndrome [Active, not recruiting]

Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women [Recruiting]

Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI) [Completed]

Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women [Completed]

A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer [Completed]

Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC Patients [Not yet recruiting]

A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg [Active, not recruiting]

Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer [Completed]

A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer [Recruiting]

Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy [Active, not recruiting]

Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours [Recruiting]

Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant [Recruiting]

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer [Recruiting]

Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer [Recruiting]

Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer [Completed]

Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer [Withdrawn]

Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer [Not yet recruiting]

Phase I Study of the Combination of MLN9708 and Fulvestrant [Recruiting]

Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer [Completed]

Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer [Recruiting]

Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy [Active, not recruiting]

Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer [Terminated]

Fulvestrant in Hormone Refractory Prostate Cancer [Completed]

Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients [Completed]

A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast Cancer [Completed]

A Study, Comparing a Dose-Titration Regimen of Fulvestrant With the Approved Dosing Regimen in Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer (ABC) [Recruiting]

Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer [Completed]

A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer [Recruiting]

A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer [Recruiting]

SANDPIPER Study: A Study Of Taselisib + Fulvestrant Versus Placebo + Fulvestrant In Patients With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy [Recruiting]

Retrospective Brazilian Study of Fulvestrant in Advanced Breast Cancer [Completed]

Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer [Active, not recruiting]

Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France [Completed]

Faslodex Registry: Fulvestrant in Current Clinical Practice [Completed]

Faslodex Post Marketing Surveillance [Completed]

AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer [Active, not recruiting]

Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC [Recruiting]

Faslodex Specific Clinical Experience Investigation [Completed]

Quality Of Life While Receiving Faslodex [Completed]

Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy [Completed]

SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex� After Aromatase Inhibitor Failure in Advanced Breast Cancer [Completed]

Fulvestrant in Postmenopausal Patients With Metastatic Breast Cancer [Completed]

A Trial to Evaluate the Combination of Iressa & Faslodex� in Patients With Advanced or Metastatic Breast Cancer [Completed]

Fulvestrant in Treating Patients With Recurrent Prostate Cancer [Terminated]

Faslodex International Observational Non-Interventional Study in Advanced Breast Cancer (BC) [Completed]

Retrospective Study Assessment Treatment Response Faslodex®( 500 mg) [Recruiting]

Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy [Terminated]

Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA in Postmenopausal Women With Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer [Completed]

Parameters of Acceptability, Compliance and Efficacy of Fulvestrant in Post-menopausal Patients With Advance Breast Cancer [Completed]

Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer [Completed]

Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer [Terminated]

Fulvestrant (Faslodex) + Anastrozol (Arimidex) vs Anastrozol [Terminated]

Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer [Active, not recruiting]

Molecular Imaging of Fulvestrant Effects on Availability of ER Binding Sites [Completed]

A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS) [Terminated]

Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer [Completed]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017